A Pilot Study of Use of Calcium Channel Blocker to Decrease Inflammation and Pain in Hereditary Pancreatitis
Pancreatitis
About this trial
This is an interventional treatment trial for Pancreatitis focused on measuring pancreatitis, hereditary, trypsinogen, cationic, pilot study
Eligibility Criteria
Inclusion Criteria: mutation in cationic trypsinogen (PRSS1)gene age 6 years and above able to comply with study terms: taking daily oral medication, taking daily blood pressure, filling in daily symptoms diary, coming to all follow-up visits having some symptoms of pain from pancreas Exclusion Criteria: combination of mutations in the 2 other loci associated with pancreatitis: Cystic fibrosis transmembrane regulator and serine protease inhibitor Kazal type 1 (having mutations in both genes) pancreatic insufficiency (exocrine and endocrine) already being on an antihypertensive medication contraindication to taking amlodipine (allergic reaction, severe renal failure (creatinine > 3 mg/dL; hepatic dysfunction signified by INR > 1.5) pregnancy or breastfeeding systemic disease that the investigators feel would place patient at undue risk of being placed on amlodipine newly-started (within past 3 months) pancreatic enzymes, acid blocking medication, antioxidants, or oral contraceptive medication
Sites / Locations
- General Clinical Research Center, University of Pittsburgh